Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rasha Cosman"'
Autor:
Yulong Zheng, Anna Rachelle Austria Mislang, Jermaine Coward, Rasha Cosman, Adam Cooper, Craig Underhill, Jianqing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, Dennis Xia, Yu Xia, Nong Xu
Publikováno v:
Cancer Immunology, Immunotherapy. 71:2371-2379
The safety and anti-tumor activity of penpulimab in patients with advanced upper gastrointestinal (UGI) cancers were evaluated in this study.Patients with advanced UGI cancers naive to immune checkpoint inhibitors were enrolled in two trials of penpu
Autor:
Gerald B. Fogarty, Ellen Charalambous, Georgia Graham, Chelsie O’ Connor, Monique Heinke, Morton Rawlin, Roger Haddad, Philip Tong, Elizabeth J. Paton, Rasha Cosman
Publikováno v:
International Journal of Radiology & Radiation Therapy. 9:14-20
Introduction: Complex skin cancers (CSCs) may benefit from review by a specialist skin multidisciplinary team (MDT). Accessing an MDT may be difficult for practitioners in non-metropolitan settings. Technology has been promoted as a solution. We deci
Autor:
Subotheni Thavaneswaran, Frank P Lin, Maya Kansara, John P Grady, David Espinoza, Anthony M Joshua, Peter Grimison, Paul Craft, Rasha Cosman, Chee Lee, Kathleen Harwood, Sarah Chinchen, Theresa Corpuz, Mandy Ballinger, Lucille Sebastian, John Simes, David Thomas
Immune checkpoint blockade impedes the negative regulatory signals for T-cell response and permits more effective immune detection and eradication of cancer cells. This single-arm phase II clinical trial (ACTRN12616001019493) within the Molecular Scr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::741aee1f1708d70c6b8b1d85eede4edd
https://doi.org/10.1101/2022.06.30.22277092
https://doi.org/10.1101/2022.06.30.22277092
Autor:
Jordi Rodon, Lipika Goyal, Teresa Macarulla Mercade, Masafumi Ikeda, Shunsuke Kondo, Do-Youn Oh, Li-Yuan Bai, Makoto Ueno, Antoine Italiano, Kyriakos Papadopoulos, David Spigel, Sani H. Kizilbash, Rasha Cosman, Joon Oh Park, Li-Tzong Chen, Tomoya Yokota, Anita A. Turk, Chih-Yi Liao, Rachna Shroff, Anthony El-Khoueiry, Taroh Satoh, Antoine Hollebecque, Mitesh J. Borad, Nilofer Azad, Kurt A. Jaeckle, Herbert H. Loong, Jorge Adeva, Wei Peng Yong, Junjie Zhao, Hui Liu, Anna M. Szpurka, Ivelina Gueorguieva, Kamnesh R. Pradhan, Xiaojian Xu, James J. Harding
Publikováno v:
Cancer Research. 83:CT098-CT098
Background: Isocitrate dehydrogenase 1/2 (IDH1/2) is mutated in a subset of cholangiocarcinoma (CCA), gliomas, and other solid tumors. LY3410738 is a potent, selective, covalent, dual inhibitor of IDH1/2 mutations (IDH1/2m). LY3410738 binds covalentl
Autor:
Sumayah Jamal, Adnan Nagrial, Matteo Carlino, Rasha Cosman, Anthony Joshua, Richard Eek, Sarina Piha-Paul, Omid Hamid, Jenny Liu
Publikováno v:
Cancer Research. 83:CT267-CT267
Programmed cell death 1 (PD-1) inhibitors have minimal effect in ovarian cancer (OC) and pancreatic ductal adenocarcinoma (PDAC). Selective endothelin B receptor (ETBR) blockade stimulates T cell tumor infiltration and synergizes with anti-PD-1 thera
Autor:
Gopa Iyer, Arlene Siefker-Radtke, Matthew Milowsky, Neal Shore, Xin Gao, Melissa A. Reimers, Noah Hahn, Rasha Cosman, Nobuaki Matsubara, Andrea Necchi, Debbie Robbrecht, Armelle Vinceneux, Enrique Grande, Jae-Lyun Lee, Tian Zhang, Tormod Guren, Ulrich M. Lauer, Michal Sarfaty, Bernhard Eigl, Syed Hussain, Xiang Zhao, Arjun V. Balar, Kaitlyn Francese, Ryan Widau, Benjamin Garmezy
Publikováno v:
Cancer Research. 83:CT119-CT119
Background: Alterations in the fibroblast growth factor receptor 3 (FGFR3) have been identified as oncogenic drivers in several solid tumor malignancies, including urothelial carcinoma (UC). Available pan-FGFR inhibitors target all 4 isoforms of FGFR
Autor:
Jayesh Desai, Sae-Won Han, Jong-Seok Lee, Einat Shacham-Shmueli, Erminia Massarelli, Andrés Cervantes, Elena Garralda, Alejandro Falcon, Wilson H. Miller, Eelke Gort, Thomas Karasic, Salvatore Siena, Rafal Stec, Laura Medina, Luis Paz-Arez, Angelo Delmonte, Adrian Sacher, Hans Prenen, Martin Forster, Tae Won Kim, Matthew G. Krebs, Rasha Cosman, Yoonha Choi, Sandhya Mandlekar, Mark T. Lin, Kenneth K. Yau, Julie Chang, Stephanie Royer-Joo, Neekesh V. Dharia, Jennifer L. Schutzman, Manish Patel
Publikováno v:
Cancer Research. 83:CT029-CT029
Background: GDC-6036 is an oral, highly potent and selective KRAS G12C inhibitor that demonstrated anti-tumor activity in patients with KRAS G12C-positive advanced solid tumors, including CRC. In a previously reported single-agent cohort, GDC-6036 ac
Autor:
Alison M. Schram, Vivek Subbiah, Ryan Sullivan, Rasha Cosman, Jia Liu, Eric I. Sbar, Thuy Hoang, Jiarong Chen, Mark Johnson, Vincent Amoruccio, Todd Shearer, Adeela Kamal, Jocelyn Lewis, Wenlin Shao, Badreddin Edris, Lusong Luo, Jayesh Desai
Publikováno v:
Cancer Research. 83:CT031-CT031
Background: BGB-3245 is a RAF dimer inhibitor with preclinical activity in MAPK-altered tumor models harboring BRAF V600 mutations, atypical BRAF mutations/fusions, and RAS mutations. This study is investigating the safety, pharmacokinetics, and prel
Autor:
Shubham Pant, Martin H. Schuler, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Dirk Arnold, Martin Gutierrez, Hans Prenen, Gunnar Folprecht, Helen Winter, Rasha Cosman, Graziela Zibetti Dal Molin, Qi Xia, Saltanat Najmi, Constance Hammond, Shibu Thomas, Spyros Triantos, Hussein Sweiti, Yohann Loriot
Publikováno v:
Journal of Clinical Oncology. 41:610-610
610 Background: Erdafitinib (erda) is an oral selective pan-FGFR tyrosine kinase inhibitor approved to treat locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2alt who have progressed during or after ≥1 line of pl
Autor:
Luke Ardolino, Ronghua Zhao, Eugene Hsu, Rasha Cosman, Neha Aggarwal, Anthony M. Joshua, William Jia, Aaron O'Grady, Erica Lee, Yanal M. Murad, Huiqun Xia, Yiting Chi, Shi Qui
Publikováno v:
Journal of Clinical Oncology. 39:e14574-e14574
e14574 Background: Oncolytic virus (OV) can specifically replicate in cancer cells causing cell lysis. Together with the expression of immune stimulating payloads, OV can induce an anti-tumor immune response. The aim of this study is to assess the sa